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Introduction
Despite advances in wound care, the increasing inci-
dence of chronic wounds and their numerous socioe-
conomic consequences have made wound
management a key area of focus for health profes-
sionals. Several thousand pounds are devoted annu-
ally to research in this area (1).
Debridement is an essential component of wound
care, as the ‘necrotic burden’ supported by devital-
ised tissue impedes the healing process (2,3). In
recent years there has been renewed interest into the
use of maggots for biosurgical debridement.
Larval therapy (or sometimes known as thera-
peutic myiasis) is by no means a modern idea,
having been used for several hundred years in
wound healing by several cultures, including Mayan
Indians and Australian aborigines (4). The benefi-
cial effects of therapeutic myiasis were first
observed during the Napoleonic war by Larrey,
who noted that soldiers whose wounds had become
infested with maggots had an improved prognosis.
During the First World War, Baer documented the
successful treatment of leg ulcers and osteomyelitis
using larval therapy, and paved the way for further
use of it by doctors of that time. However, the
development of antibiotics and improvements in
surgical techniques reduced larval therapy to a
‘treatment of last resort’, reserved for the most
intractable wounds (5).
The emergence of antibiotic-resistant strains of
bacteria such as methicillin resistant Staphylococcus
aureus (MRSA) and the curiosity of researchers
has prompted a resurgence of interest in larval
therapy (6). As a treatment it meets the
demands of clinical governance, being not only
beneficial to the patient, but also being proven to
be more cost-effective (7). However, application
of larval therapy has been stifled by aesthetic con-
siderations.
Applications of larval therapy
Whilst the effects of therapeutic myiasis were ini-
tially recorded in suppurative wounds on the bat-
tlefield, numerous case studies have reported its
successful use with a variety of wounds. Larval
therapy has been employed effectively to treat a
wide spectrum of wounds including venous and
arterial leg ulcers, osteomyelitis, necrotising fasciitis,
traumatic necrotic leg wounds, primary burns,
pressure sores and amputation sites including digi-
tal amputations in diabetic feet (8). Larval therapy
has also been used for the treatment of a variety
of intractable wounds, including sacral and leg
ulcers of assorted aetiologies (9). Case studies have
reported the successful use of larval therapy to
treat a wide variety of wounds including chronic
diabetic ischaemic foot ulcers (10); necrotic ulcer-
ation caused by repetitive footwear trauma of a
localised foot metastasis (11); bilateral neuropathic
foot ulceration (12) and chronic diabetic foot
ulcers (13–15). In all cases, the wounds were suc-
cessfully debrided of devitalised tissue and granula-
tion tissue developed rapidly.
SUMMARY
Debridement is an essential component of wound care as the presence of devital-
ised tissue can impede the healing process. Larval therapy has been used for the
debridement of wounds for several hundred years. A plethora of literature is avail-
able on larval therapy, but many authors acknowledge the paucity of large-scale
clinical trials supporting its effectiveness. While the exact mechanism of larval ther-
apy remains unknown, it encompasses three processes: debridement, disinfection
and promotion of healing. This literature review discusses the applications, benefits
and disadvantages of larval therapy as well as the processes involved. The litera-
ture reviewed suggests that further comprehensive research into the mechanisms
involved in larval therapy is required to ensure that it may be used to best medical
advantage.
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Message for the Clinic
Whilst larval therapy is not suitable for all wounds,
it should not be viewed as a treatment of last
resort.
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General benefits of larval therapy
Anecdotal evidence has consistently suggested that
larval therapy results in a reduction in wound pain
and odour, and promotes the healing process with
relatively few side effects (16–18). Larval therapy is
also reported as being cost-effective in comparison
with conventional wound dressings (19). An import-
ant study investigated the efficacy and cost-effective-
ness of larval therapy vs. hydrogel, and reported that
all wounds treated with larval therapy were success-
fully debrided following one application at a median
cost of £78.64 (20). Treatment with hydrogel was
proven to be less efficient where it was noted that,
following 1 month of treatment, one-third of
wounds still continued to require treatment. The
median cost of treatment for this group was £136.23.
However, the study involved only 12 patients (six
within each group) and thus lacked an adequate
number of patients required for large-scale trials to
support the efficacy of treatment. The use of larval
therapy often resulted in quicker healing, and a sub-
sequent reduction of nursing time and materials
(19). Larval therapy has become available on
the drug tariff, thus further increasing its cost-
effectiveness.
A further advantage of larval therapy is that, as
larvae are typically applied for 3 days, wounds are
disturbed less frequently than conventional dressings
that require changing every 1–2 days (21). In addi-
tion to this, a further advantage is that treatment can
usually be carried out in outpatient and community
settings. A study at an outpatient wound clinic on
chronic wounds of varying aetiologies reported that
using larval therapy resulted in a 62% decrease in
the need for amputation (22).
Larval therapy and multi-resistance
The use of antibiotics to treat chronic wounds has
lead to the emergence of ‘resistant’ bacteria. Such
strains possessed an evolutionary advantage, and
were able to increase their population size through
Darwinian selection (23). Despite the pharmaceutical
response in the form of other antibiotics such as
erythromycin and methicillin, further evolution of
microbial drug resistance has occurred at a rapid
rate, and to a point where antimicrobial resistance
has become a major threat to public health (24). The
recent development of vancomycin resistance has
created an imperative need for alternative methods
of treating infection (25). The most predominant
microorganisms of concern include Escherichia coli
(E. coli), Pseudomonas aeruginosa and MRSA. MRSA
has become a frequent cause of nosocomial infec-
tions and ‘epidemic’ strains have consequently
become the focus of much media attention in recent
years (26).
Larvae offer the benefit of eliminating bacteria
from the wound through ingestion and subsequent
degradation within their intestinal tract (27). They
also act to reduce bacterial activity through the pro-
duction of inhibitory secretions. Such actions appear
to hold true for MRSA as well as other multi-resist-
ant microorganisms, such as Pseudomonas species.
While the literature suggests that larval therapy is less
effective in wounds infected with E. coli (28), this
has since been called into question. In vitro research
examining the ingestion by Lucidia sericata larvae of
E. coli (which produced a green fluorescent protein)
showed a gradual decrease in fluorescence from the
anterior section of the larval alimentary canal to its
end, thus demonstrating a reduction in the level of
bacteria. It may be that a greater quantity of larvae is
required in vivo to eradicate wounds of Gram negat-
ive bacteria such as E. coli (29).
Other evidence, while anecdotal, supports the use
of larval therapy against wound pathogens. In a
recent trial, larval therapy was used successfully to
treat chronic, MRSA-infected wounds of five
patients, including heel ulceration (30). The authors
remarked on a few cases where MRSA infection was
not successfully eliminated, speculating that the treat-
ment may have been unsuccessful for reasons such as
insufficient application of larvae, or that therapy may
have been discontinued too early to allow complete
eradication of MRSA. Further research reported the
successful use of larval therapy in the treatment of
three wounds infected with MRSA, however, the
author failed to describe the types of wound, their
location and their duration (8).
Preliminary research has indicated that the puri-
fied secretions of sterile, aseptically raised L. sericata
larvae exhibited antibacterial activity against MRSA
in vitro; although activity was found to be bacterio-
static rather than bactericidal (28). The authors
remarked that the degree of inhibition may have var-
ied as a result of the methods used for the collection
of the secretions. Subsequently, it was suggested that
the study undervalued the effects of larval secretions,
as they are produced continuously in vivo and thus
concentrations within the wound would be greater.
The authors proposed that a stronger action against
the growth of MRSA and other multi-resistant
microorganisms could therefore be expected.
A recent study supported this research, finding
that secretions from L. sericata larvae displayed
potent antibacterial action against MRSA (31). It was
reported that the most significant antibacterial activ-
ity was from a small fraction of larval secretion with
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a molecular weight of <500 Da. However, antibacter-
ial activity was dependent on the selection of an
appropriate type of bioassay and optimal conditions.
The dilution of larval secretions was believed to have
influenced the findings (28).
Disadvantages of larval therapy
The most commonly mentioned disadvantage of lar-
val therapy is the negative perception with which it
is regarded by both patients and practitioners
(5,18,32). Although the so-called ‘yuk factor’ of its
clinical appearance (Figure 1) has been frequently
reported in case studies, there is little evidence to
suggest that patients refuse larval therapy when it is
offered (33). The use of ‘Biobags’ (Polymedics,
Belgium), which completely enclose the larvae within
a polyvinylalcohol membrane, has become a popular
method of improving the application of this treat-
ment (Figure 2). Larvae are able to feed freely
through the open cell polymer, but are less visible to
the squeamish patient or practitioner (34).
Appropriate education, perhaps incorporated into
the continuous professional development of the prac-
titioner, may prove useful in overcoming the scepti-
cism and distaste of practitioners (8,35). Better
dissemination of information may also help address
the problem of poor survival rates of larvae during
treatment because of the lack of moisture (36).
Pain has occasionally been reported by patients
suffering from ischaemic wounds (9,37). The cause
may be the sharp mouth hooks and spicules with
which larvae anchor themselves onto tissue. Contrac-
tion of necrotic tissue or pH changes within a
wound may affect pain receptors in proximal healthy
tissue (37). Occasionally inflammation of adjacent
tissue may also pose problems for adherence of
dressings, and treatment should be delayed until
inflammation has subsided (8). Several authors have
proposed that skin surrounding the wound should
be protected using hydrocolloids or zinc paste to
prevent possible damage from powerful proteolytic
enzymes within larval secretions (33,38,39).
A case history has suggested larval therapy to be
contraindicated with fistulae, exposed vessels and
wounds connecting to vital organs (40). No occur-
rences of allergic reaction were recorded, but blood-
stream infections (with Providencia stuartii and
Candida albicans) have been reported where larvae of
Protophormia terraenovae and not L. sericata were
used (41). Alteration of the disinfection process
appeared to eliminate this problem, with no further
cases of sepsis occurring during the subsequent
12 months. The risk of cross-infection by escaped
larvae may be greatly reduced through careful dress-
ing (42), although no occurrences have been docu-
mented (43).
Mechanisms involved in larval therapy
Wound debridement
Larvae feed on necrotic tissue, cellular debris and
exudate within the wound, thus debriding it of devi-
talised tissue. In various randomised controlled clin-
ical trials, researchers noted that significantly more
wounds healed with frequent debridement, regardless
of the use of topical preparations (44,45). Debride-
ment is a critical factor in wound care, and is equally
as important as pressure relief in facilitating wound
healing (46).
Figure 1 Photograph courtesy of Medical Photography
Department, Belfast City Hospitals Trust. Larvae of Lucilia
sericata (approximately 15 mm in length) following
removal from wound (post 3 days in contact)
Figure 2 Photograph courtesy of Medical Photography
Department, United Hospitals Trust. Sterile LarvETM of
Lucilia sericata prior to wound application
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The basic mechanism of larval debridement has
been described by several researchers (47–49). The
digestive juices secreted by larvae during the feeding
process have been found to contain a variety of pro-
teolytic enzymes, including trypsin-like and chymot-
rypsin-like enzymes and collagenase (50). The
enzymes selectively debride necrotic tissue, leaving
viable tissue unharmed (1). Further research tested
the effects of larval secretions of Calliphora erythro-
cephala on experimental burns on rat skin, and
reported that the secretions had proteolytic proper-
ties in vitro and in vivo (51).
Wound disinfection
Chronic wounds are frequently colonised and infec-
ted with a variety of wound flora, including Staphy-
lococcus and Streptococcus species, P. aeruginosa and
E. coli. Increased bacterial load may impair healing,
particularly if a wound becomes infected with anti-
microbial resistant bacteria (as discussed above). Dis-
infection is therefore a critical component of wound
healing.
The natural habitats of larvae include corpses and
wounds, which typically contain a vast array of
pathogenic microorganisms. In response to these
conditions larvae are believed to have evolved several
effective mechanisms for removing bacteria. During
feeding, larvae ingest bacteria within devitalised tis-
sue thus physically removing microorganisms (52).
Research has suggested that any bacteria which are
not destroyed within the acidic alimentary canal are
contained within a tubular structure known as the
peritrophic membrane, thus preventing recontamina-
tion (53).
Movement of larvae may stimulate the production
of serous exudate by the wound, thus increasing irri-
gation and removing bacteria (1), or wounds may be
physically irrigated by larval secretions themselves
(54). Other authors believe the process to be more
complex, and suggest that larval secretions play a
greater role in wound disinfection (55). Early
research has shown that larval secretions contain a
variety of alkaline components, including ammonium
bicarbonate, calcium, allantoin and urea that inhibit
bacterial growth (56–58). The subsequent increase in
pH provides an optimum environment for enzymatic
activity, and also renders the wound bed uninhabita-
ble to many bacteria, hindering subsequent recoloni-
sation (59).
Disinfection may occur as a result of the release of
compounds in larval secretions in conjunction with
the digestion of devitalised tissue (60). It has been
proposed that larvae release antimicrobial substances
as part of an innate response to high levels of bac-
teria (3). In vitro research isolated a protease resist-
ant, thermally stable compound from larval
secretions, which exhibited strong antibacterial activ-
ity (31). Some antibacterial compounds isolated,
such as phenylacetic acid and phenylacetaldehyde,
are thought to be released by Proteus mirabilis, a
commensal species of bacteria found within the lar-
val alimentary canal (61). The symbiotic relationship
between larvae and particular bacterial species
appears to facilitate wound disinfection, but further
research is required into the mechanism.
Promotion of wound healing
Research has consisted of small-scale clinical trials
and in vitro investigations of the properties of larval
secretions. Surprisingly, as it has no benefit to the
larvae, therapy appears to encourage the formation
of granulation tissue in the wound bed and acceler-
ate wound healing (9,62).
In a comparative study of chronic wounds of mul-
tiple aetiologies, it was reported that all wounds
healed following 4 weeks of treatment with larval
therapy, whereas necrotic tissue was still present on
the surface of conventionally treated wounds follow-
ing 5 weeks (63). This finding was in agreement with
earlier work by the author who compared the healing
rates of pressure ulcers treated with either conven-
tional dressings or larval therapy (64). Several case
studies involving chronic leg ulcers have also recor-
ded the development of granulation tissue within the
wound bed (18,65,66). During an in vivo study, a
single application of larvae was applied to chronic
leg ulcers (n ¼ 30) of mixed aetiology (67). The
wounds were assessed subjectively, using a wound
scoring system, and objectively, using remittance
spectroscopy. Following treatment with larvae, remit-
tance was greatly reduced because of an increased
quantity of granulation tissue within the wound bed.
The authors concluded that larval secretions had a
positive effect on wound healing because of the
development of granulation tissue and increased tis-
sue oxygenation.
As discussed earlier, the constant movement of lar-
vae within the wound is believed to mechanically sti-
mulate the wound bed (68). However, use of
‘Biobags’ that inhibit mechanical stimulation has also
resulted in improved healing, suggesting that factors
other than mechanical stimulation are involved
(34,69).
The properties of substances within larval secre-
tions, described as a healing ‘active principle’
(56,58), have been the subject of subsequent research
and suggested that the secretion of allantoin, ammo-
nium bicarbonate and urea provide an optimal
growth environment for cells involved in wound
healing by acting as growth factors (70,71). The alka-
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line nature of these substances has been reported to
have a role in the promotion of healing by altering
the pH of the wound (72).
In vitro research noted that whilst larval secretions
stimulated growth of human fibroblast growth, the
effect was increased when combined with epidermal
growth factor (73). The results indicated that secre-
tions may enhance healing through interaction with
compounds released by the wound. This research
demonstrated for the first time that the insect moult-
ing hormone, 20-hydroxyecdysone, stimulates fibro-
blast growth. It was suggested that the resultant
tissue proliferation within the wound stimulated by
the release of growth factors may provide larvae with
better nourishment.
Further research investigated the in vitro effects of
larval secretions on human dermal neonatal fibro-
blast cells and reported that the presence of secre-
tions resulted in a reduction in fibroblast adhesion
to fibronectin and collagen (which are constituents
of the extracellular matrix modification) (74). The
authors suggested that this may be due to proteolytic
activity of larval secretions altering the structure of
the extracellular matrix. They postulated that this
behavioural modification within the wound may pro-
mote the formation of new tissue. This supported
earlier work proposing that the activity of trypsin-
like and chymotrypsin-like proteinases strongly influ-
enced the remodelling of the extracellular matrix
(62).
Conclusion
From the literature reviewed it can be noted that as
a treatment, larval therapy offers numerous advan-
tages including rapid wound debridement and elim-
ination of infection, control of pain and odour, and
the promotion of wound healing. Use of larval ther-
apy has resulted in few side effects, and has reduced
the need for amputation (22). It is also apparent that
the treatment also offers an efficient alternative to
antibiotic therapy for the treatment of wounds con-
taminated with a variety of wound pathogens, inclu-
ding MRSA and E. coli. Having been largely
superseded by antibiotics, larval therapy has
re-emerged as one of the current strategies for target-
ing microbial resistance.
It is apparent that the literature consists mainly of
case studies into the applications of larval therapy.
Large-scale clinical trials are required to further
examine the efficacy of the process and its effects on
healing times. Overall, larval therapy facilitates the
efficient and selective debridement of devitalised tis-
sue. The treatment has the added benefit of being
bactericidal whilst functioning in harmony with
wound processes to promote healing. Whilst not
suitable for all wounds, larval therapy should no lon-
ger be viewed as a treatment of last resort.
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